I believe these 2 FTSE 100 giants are good value right now!

Jabran Khan identifies two FTSE 100 giants that he believes could see a share price increase and positive fortunes ahead.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I think FTSE 100 incumbents Barclays (LSE:BARC) and GlaxoSmithKline (LSE:GSK) could be good additions to my portfolio at current levels as I believe they are undervalued. Here’s why I would be willing to buy at current levels. 

FTSE 100 banking giant

Looking at Barclays share price activity, I see value based on current levels. Looking at its 52-week high and low, it had a high of 190p per share and a low of 88p per share, which is less than half the high. As I write, shares are trading for 182p per share.

I understand that Barclays’ share price increase is not a guarantee, however. If the FTSE 100 incumbent’s impressive H1 report is anything to go by, further trading updates could result in a share price increase. The report showed profit before tax of £5bn. This is a considerable increase from H1 2020 with profit of £1.3bn.

Barclays also offers a dividend. Its yield is below the consensus FTSE 100 level of 3% but would make me a passive income nonetheless. I believe shares could the reach 190p in the coming weeks. If I purchased 100 shares at current levels and the price did go up, I could make approximately £1,000 in just a few weeks, for example.

FTSE 100 pharma giant

As I write, shares in GSK are trading for 1,411p per share. The share price has slumped in the past month from 1,525p on 25 August to current levels, which is an 8% drop. I believe this is due to its recent announcement that it is spinning off its consumer healthcare business, provisionally called New GSK. There will also be a cut in dividends, from 80p per share to a better-than-expected 55p per share. New GSK will offer a dividend of 45p per share starting from 2023.

Looking at GSK’s 52-week high and low is where I get my confidence that the share price will rise once more after the dust settles from this announcement. In addition to this, the FTSE 100 incumbent will benefit from the British economy stabilizing further. The stock’s highest price in the past 52 weeks was 1,533p per share and lowest was 1,190p per share.

GSK continues to work hard on developing new drugs. In April, it reported it had won approval to market Jemperli, an endometrial cancer drug it had developed. Progress such as this will also bump up its value.

Risks involved

As a savvy investor, I must consider the risks of both FTSE 100 giants before investing my cash.

Barclays’ primary risk is linked to the state of the world economy and the pandemic. The pandemic did negatively affect operations and financials previously. If new variants and restrictions are introduced, this could hamper it once more.

GSK’s position as one of the biggest pharma firms in the world is a heavy crown to maintain. One risk is its promise to have a net zero impact on the climate by 2030. This will not be an easy feat. If it is unable to achieve this, the negative reaction could hurt its reputation and financials. Performance is also vital as GSK invests heavily in research and development (R&D). If it struggles or hits any roadblocks, R&D could be affected which will hurt future performance too.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jabran Khan has no position in any shares mentioned. The Motley Fool UK has recommended Barclays and GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 industry-leading value stocks investors should consider buying

These value stocks are at the top of their respective industries, and look like current bargains with the potential to…

Read more »

Black father and two young daughters dancing at home
Investing Articles

Just released: our 3 top small-cap stocks to buy before August [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

If I’d put £5k in a FTSE 100 index fund 10 years ago, here’s what I’d have now!

Charlie Carman explores the performance of the FTSE 100 index over the past decade and the merits of passive versus…

Read more »

Investing Articles

£15K stashed away? I could turn that into a second income worth £49 a day!

This Fool explains how she would look to gain a second income through investing in UK stocks, and the steps…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

With the Apple share price near an all-time high, would I be crazy to buy more?

After touching all-time highs yesterday, the Apple share price is on a roll. But is there still enough growth ahead…

Read more »

Investing Articles

Nvidia stock has fallen 13% from its 52-week high! What next?

Our writer explains why Nvidia stock has dipped recently and highlights some risks associated with investing in the AI leader…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

The AstraZeneca share price is up 88% in 5 years, but is it just getting started?

The AstraZeneca share price has had a great few years, as acquisitions and clinical trials delighted shareholders. So is there…

Read more »

Investing Articles

Here’s why I’m watching the Anglo American share price

The mining sector has always interested investors. But after a flat few years, I'm wondering what's next for the Anglo…

Read more »